Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005755 · ClinicalTrials.gov registry record · Phase 3
Maxigesic® IV Phase 3 Exposure Study
A Phase 3 study, sponsored by AFT Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT04005755: Completed Phase 3 study, sponsored by AFT Pharmaceuticals.
NCT04005755 is a Phase 3 study that has completed, run by AFT Pharmaceuticals. The registered enrollment target is 232 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04005755, a Phase 3 study, has completed, sponsored by AFT Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
Primary Outcome
The incidence of treatment-emergent adverse events associated with exposure Maxigesic® IV
Interventions
- DRUG Maxigesic® IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-07-07 |
| Phase | Phase 3 |
What the finished NCT04005755 record still lists
NCT04005755 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Maxigesic® IV is the first listed.
NCT04005755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04005755 about?
NCT04005755 is a clinical study titled "Maxigesic® IV Phase 3 Exposure Study". The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
What is the current status of trial NCT04005755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2019-07-22. Estimated completion is 2020-07-07.
What interventions are being tested in trial NCT04005755?
The interventions under investigation include: Maxigesic® IV (DRUG).
Who is sponsoring clinical trial NCT04005755?
This trial is sponsored by AFT Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04005755's enrollment target sits among peer trials
232 1298th of 2000 higher than 701 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI